Targeting	O
a	O
tumor	B-Cancer
-	O
specific	O
laminin	O
domain	O
critical	O
for	O
human	O
carcinogenesis	O
.	O

Laminin	O
-	O
332	O
is	O
critical	O
for	O
squamous	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
(	O
SCC	B-Cancer
)	O
tumorigenesis	O
,	O
but	O
targeting	O
it	O
for	O
cancer	B-Cancer
therapy	O
has	O
been	O
unachievable	O
due	O
to	O
key	O
role	O
of	O
laminin	O
-	O
332	O
in	O
promoting	O
tissue	B-Tissue
integrity	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
portion	O
of	O
laminin	O
-	O
332	O
,	O
termed	O
G45	O
,	O
which	O
is	O
proteolytically	O
removed	O
and	O
absent	O
in	O
normal	O
tissues	B-Tissue
,	O
is	O
prominently	O
expressed	O
in	O
most	O
human	O
SCC	B-Cancer
tumors	I-Cancer
and	O
plays	O
an	O
important	O
role	O
in	O
human	O
SCC	B-Cancer
tumorigenesis	O
.	O

Primary	O
human	O
keratinocytes	B-Cell
lacking	I-Cell
G45	I-Cell
(	O
DeltaG45	B-Cell
)	O
showed	O
alterations	O
of	O
basal	O
receptor	O
organization	O
,	O
impaired	O
matrix	B-Cellular_component
deposition	O
,	O
and	O
increased	O
migration	O
.	O

After	O
SCC	B-Cancer
transformation	O
,	O
the	O
absence	O
of	O
G45	O
domain	O
in	O
DeltaG45	B-Cell
cells	I-Cell
was	O
associated	O
with	O
deficient	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
phosphotidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
activation	O
,	O
impaired	O
invasion	O
,	O
deficient	O
metalloproteinase	O
activity	O
,	O
and	O
absent	O
tumorgenicity	O
in	O
vivo	O
.	O

Expression	O
of	O
G45	O
or	O
activated	O
PI3K	O
subunit	O
in	O
DeltaG45	B-Cell
cells	I-Cell
reversed	O
these	O
abnormalities	O
.	O

G45	O
antibody	O
treatment	O
induced	O
SCC	B-Cancer
tumor	I-Cancer
apoptosis	O
,	O
decreased	O
SCC	B-Cancer
tumor	I-Cancer
proliferation	O
,	O
and	O
markedly	O
impaired	O
human	O
SCC	B-Cancer
tumorigenesis	O
in	O
vivo	O
without	O
affecting	O
normal	O
tissue	B-Tissue
adhesion	O
.	O

These	O
results	O
show	O
a	O
remarkable	O
selectivity	O
of	O
expression	O
and	O
function	O
for	O
laminin	O
-	O
332	O
G45	O
in	O
human	O
SCC	B-Cancer
tumorigenesis	O
and	O
implicate	O
it	O
as	O
a	O
specific	O
target	O
for	O
anticancer	B-Cancer
therapy	O
.	O

